Schrödinger, Eli Lilly Strike $425M Small Molecule Deal

Computational technology company Schrödinger has forged a drug design collaboration with Eli Lilly, Schrödinger announced Thursday.

Schrödinger will receive up to $425M and be responsible for the discovery and optimization of small molecule compounds addressing an undisclosed target. Once that is complete, Indianapolis-based Eli Lilly will then be responsible for the completion of preclinical development, clinical development and commercialization.